Tag: Cabotegravir

As of 2025, there is no therapeutically equivalent generic version of CABENUVA available in the United States. This injectable HIV treatment, a combination of cabotegravir and rilpivirine, remains a brand-name-only medication due to patent protection.

The FDA approved the first long-acting injectable medication for HIV pre-exposure prophylaxis (PrEP) in late 2021. The primary brand-name for cabotegravir for PrEP, an integrase inhibitor that prevents HIV from establishing an infection, is Apretude.

Despite the rising prevalence of long-acting injectable treatments, a direct generic equivalent for CABENUVA does not yet exist on the market. Understanding what is the generic for CABENUVA requires a closer look at its two active components and the complex process of patent exclusivity.

The list price for Apretude, the injectable form of cabotegravir for PrEP, is approximately $4,125 per dose, which is administered every two months [1.2.1, 1.2.3]. This article breaks down the factors influencing the final answer to 'How much does cabotegravir cost?'.

As of late 2025, there is no therapeutically equivalent generic cabotegravir available for commercial use in the United States, although efforts via the Medicines Patent Pool aim to provide access in low- and middle-income countries. This article addresses the question, is there a generic for cabotegravir, and details the current situation regarding brand-name formulations and global access initiatives.